ArticleJournal of pharmaceutical health care and sciences2025
Renal maturation and catch-up clearance of ganciclovir in a preterm neonate: Bayesian pharmacokinetic analysis using a population model.
Article in Journal of pharmaceutical health care and sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Ganciclovir for severe neonatal varicella pneumonia when acyclovir is unavailable: a case report.Virology journal · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundCongenital cytomegalovirus (CMV) infection is a major cause of neonatal morbidity. However, optimizing ganciclovir (GCV) dosing in preterm infants is complicated by immature renal function and developmental pharmacokinetics. Population pharmacokinetic (PPK) parameters for GCV and valganciclovir (VGCV) have been reported, but data remain limited for extremely low birth weight infants. We aimed to characterize longitudinal changes in GCV clearance in a preterm infant with congenital CMV infection using Bayesian modeling.
methodsGCV/VGCV were administered over a 15-week period, with concurrent therapeutic drug monitoring. Individual parameters were estimated using a previously published PPK model and a postnatal age-based maturation function in NONMEM. Scr clearance was measured at two time points using the 24-h urine collection method.
resultsGCV clearance increased from 0.048 to 0.273 L/hr/kg from postnatal day 30 to day 93, whereas VGCV bioavailability remained stable (~ 52-55%). Scr clearance values matched estimated GCV clearance, supporting the validity of the model. The maturation function indicated that tubular secretion likely contributes to accelerated drug elimination. Late-phase GCV clearance exceeded typical glomerular filtration rate, indicating possible catch-up in renal function.
conclusionRenal maturation should be considered in addition to body weight when adjusting GCV dosing in preterm infants. This case highlights the importance of aligning individualized dosing strategies with the developmental physiology of preterm neonates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.